TY - JOUR
T1 - Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial
AU - Loguercio, Carmela
AU - Andreone, Pietro
AU - Brisc, Ciprian
AU - Brisc, Michaela Cristina
AU - Bugianesi, Elisabetta
AU - Chiaramonte, Maria
AU - Cursaro, Carmela
AU - Danila, Mirela
AU - De Sio, Ilario
AU - Floreani, Annarosa
AU - Freni, Maria Antonietta
AU - Grieco, Antonio
AU - Groppo, Marzia
AU - Lazzari, Roberta
AU - Lobello, Salvatore
AU - Lorefice, Elisabetta
AU - Margotti, Marzia
AU - Miele, Luca
AU - Milani, Stefano
AU - Okolicsanyi, Lajos
AU - Palasciano, Giuseppe
AU - Portincasa, Piero
AU - Saltarelli, Patrizia
AU - Smedile, Antonina
AU - Somalvico, Francesco
AU - Spadaro, Aldo
AU - Sporea, Ioan
AU - Sorrentino, Paolo
AU - Vecchione, Raffaela
AU - Tuccillo, Concetta
AU - Blanco, Camillo Del Vecchio
AU - Federico, Alessandro
PY - 2012
Y1 - 2012
N2 - The only currently recommended treatment for nonalcoholic fatty liver disease (NAFLD) is lifestyle modification. Preliminary studies of silybin showed beneficial effects on liver function. Realsil (RA) comprises the silybin phytosome complex (silybin plus phosphatidylcholine) coformulated with vitamin E. We report on a multicenter, phase III, double-blind clinical trial to assess RA in patients with histologically documented NAFLD. Patients were randomized 1:1 to RA or placebo (P) orally twice daily for 12 months. Prespecified primary outcomes were improvement over time in clinical condition, normalization of liver enzyme plasma levels, and improvement of ultrasonographic liver steatosis, homeostatic model assessment (HOMA), and quality of life. Secondary outcomes were improvement in liver histologic score and/or decrease in NAFLD score without worsening of fibrosis and plasma changes in cytokines, ferritin, and liver fibrosis markers. We treated 179 patients with NAFLD; 36 were also HCV positive. Forty-one patients were prematurely withdrawn and 138 patients analyzed per protocol (69 per group). Baseline patient characteristics were generally well balanced between groups, except for steatosis, portal infiltration, and fibrosis. Adverse events (AEs) were generally transient and included diarrhea, dysgeusia, and pruritus; no serious AEs were recorded. Patients receiving RA but not P showed significant improvements in liver enzyme plasma levels, HOMA, and liver histology. Body mass index normalized in 15% of RA patients (2.1% with P). HCV-positive patients in the RA but not the P group showed improvements in fibrogenesis markers. This is the first study to systematically assess silybin in NAFLD patients. Treatment with RA but not P for 12 months was associated with improvement in liver enzymes, insulin resistance, and liver histology, without increases in body weight. These findings warrant further investigation.
AB - The only currently recommended treatment for nonalcoholic fatty liver disease (NAFLD) is lifestyle modification. Preliminary studies of silybin showed beneficial effects on liver function. Realsil (RA) comprises the silybin phytosome complex (silybin plus phosphatidylcholine) coformulated with vitamin E. We report on a multicenter, phase III, double-blind clinical trial to assess RA in patients with histologically documented NAFLD. Patients were randomized 1:1 to RA or placebo (P) orally twice daily for 12 months. Prespecified primary outcomes were improvement over time in clinical condition, normalization of liver enzyme plasma levels, and improvement of ultrasonographic liver steatosis, homeostatic model assessment (HOMA), and quality of life. Secondary outcomes were improvement in liver histologic score and/or decrease in NAFLD score without worsening of fibrosis and plasma changes in cytokines, ferritin, and liver fibrosis markers. We treated 179 patients with NAFLD; 36 were also HCV positive. Forty-one patients were prematurely withdrawn and 138 patients analyzed per protocol (69 per group). Baseline patient characteristics were generally well balanced between groups, except for steatosis, portal infiltration, and fibrosis. Adverse events (AEs) were generally transient and included diarrhea, dysgeusia, and pruritus; no serious AEs were recorded. Patients receiving RA but not P showed significant improvements in liver enzyme plasma levels, HOMA, and liver histology. Body mass index normalized in 15% of RA patients (2.1% with P). HCV-positive patients in the RA but not the P group showed improvements in fibrogenesis markers. This is the first study to systematically assess silybin in NAFLD patients. Treatment with RA but not P for 12 months was associated with improvement in liver enzymes, insulin resistance, and liver histology, without increases in body weight. These findings warrant further investigation.
KW - non alcoholic fatty liver disease
KW - silybin
KW - trial
KW - non alcoholic fatty liver disease
KW - silybin
KW - trial
UR - http://hdl.handle.net/10807/15837
U2 - 10.1016/j.freeradbiomed.2012.02.008
DO - 10.1016/j.freeradbiomed.2012.02.008
M3 - Article
SN - 0891-5849
VL - 52
SP - 1658
EP - 1665
JO - FREE RADICAL BIOLOGY & MEDICINE
JF - FREE RADICAL BIOLOGY & MEDICINE
ER -